Employs cutting-edge polymer-free nanocarrier technology for sustained drug delivery by incorporating innovative abluminal and fusion coatings, delivering comprehensive coverage for optimal vascular repair and management of arterial lesions. A boon for reduction in antiplatelet therapy.
Only approved polymer-free Sirolimus DES with fusion coating
A boon for reduction in antiplatelet therapy
CE Approved
02
Diabetes Mellitus
Acute Myocardial Infarction
Symptomatic CAD (ACS)
Beneficial for HBR & SDAPT* (Not Approved)
03
Technology
NanoActive™ Technology is a next-generation cardiovascular drug delivery platform that merges precision submicron engineering with proven sirolimus therapy to optimize drug efficacy. Utilizing submicron-based drug carriers, it enhances drug penetration & uniform distribution within the vessel wall.
By leveraging the volume-to-surface ratio principle, NanoActive™ ensures maximum coverage, enabling deep tissue penetration up to the adventitia for effective in-tissue drug release. This controlled, localized drug delivery approach minimizes systemic exposure while maximizing therapeutic benefits.
Polymer-Free Coating
Polymer-free coating reduces inflammation and clot risk by avoiding immune responses, promoting healing for safer long-term results.
Fusion Coating
Coating covers stents, balloon, and edges to ensure uniform lesion coverage and maximize drug delivery by eliminating untreated areas at the target site.
Drug Delivery
Submicron drug carrier maximizes coverage using Volume-to-Surface Ratio, enabling deep tissue penetration up to the adventitia for effective drug release.
Precision Engineered for Performance
POWERED BY NANOACTIVE Abluminus np used Nanoactive platform to deliver sirolimus via Pro healer excipient
BETTER APPOSITION & DELIVERABILITY
Advanced balloon design for complex lesions
UNIFORM COVERAGE
Abluminal stent coating + balloon shoulders prevent edge restenosis.
SAFETY & DURABILITY
Transition to BMS-like structure within months, minimizing late events.
05
Technical SpecificationsOrdering Information For Concept BVTechnical SpecificationsDRUG
| Drug | Sirolimus |
| Drug Dose | 1.12 µg/mm² |
| Drug Carrier | Phospholipid |
Stent
| Stent Material | L605 Cobalt Chromium Alloy |
| Strut Thickness | 73 µm |
| Strut Width | 80 µm (hinge) – 120 µm (strut) |
Delivery System
| Delivery System | Rx/Monorail |
| Nominal Pressure | 8 bar |
| Rated Burst Pressure | 14 bar (Do not exceed RBP) |
| Guide Wire Compatibility (max.) | 0.014’’ |
| Guiding Catheter Compatibility | 5F |
| Crossing Profie | 0.038" (Reference diameter of 3.00mm) |
| Tip Entry Profile | 0.016" |
DRUG/EXCIPIENT
Drug
Drug Dose
Drug Carrier
1.27µg/mm²
Phospholipid
Catheter design
Rapid Exchange(RX) Design
Ordering Information | Stent dia.(mm) | Stent Length(mm) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 8 | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | |
| 2.25 | EAP22508 | EAP22512 | EAP22516 | EAP22520 | EAP22524 | EAP22528 | EAP22532 | EAP22536 | EAP22540 |
| 2.50 | EAP25008 | EAP25012 | EAP25016 | EAP25020 | EAP25024 | EAP25028 | EAP25032 | EAP25036 | EAP25040 |
| 2.75 | EAP27508 | EAP27512 | EAP27516 | EAP27520 | EAP27524 | EAP27528 | EAP27532 | EAP27536 | EAP27540 |
| 3.00 | EAP30008 | EAP30012 | EAP30016 | EAP30020 | EAP30024 | EAP30028 | EAP30032 | EAP30036 | EAP30040 |
| 3.50 | EAP35008 | EAP35012 | EAP35016 | EAP35020 | EAP35024 | EAP35028 | EAP35032 | EAP35036 | EAP35040 |
| 4.00 | EAP40008 | EAP40012 | EAP40016 | EAP40020 | EAP40024 | EAP40028 | EAP40032 | EAP40036 | EAP40040 |
For Concept BV
